TOLTERODINE TARTRATE

4). In case of troublesome side effects the dose may be reduced from 2 mg to 1 mg twice daily. 1). 1). Therefore, Tolterodine Tartrate is not recommended for children. Method of administration Oral use.

Due to the pharmacological effect of tolterodine it may cause mild to moderate antimuscarinic effects, like dryness of the mouth, dyspepsia and dry eyes. The table below reflects the data obtained with Tolterodine Tartrate in clinical trials and from postmarketing experience.

The most commonly reported adverse reaction was dry mouth, which occurred in 35% of patients treated with Tolterodine Tartrate tablets and in 10% of placebo treated patients. 4% of placebo treated patients. g. confusion, disorientation, delusion) have been reported after tolterodine therapy was initiated in patients taking cholinesterase inhibitors for the treatment of dementia.

4 %). 1) Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

g. 2) - Hepatic disease. 1). The clinical relevance of these findings is unclear and will depend on individual patient risk factors and susceptibilities present. e. cardiomyopathy, myocardial ischaemia, arrhythmia, congestive heart failure) -Concomitant administration of drugs known to prolong QT-interval including Class IA (e.

g. quinidine, procainamide) and Class III (e. g. 1). 5). As with all treatments for symptoms of urgency and urge incontinence, organic reasons for urge and frequency should be considered before treatment. This medicine contains less than 1 mmol sodium (23mg) per film-coated tablet, that is to say essentially ‘sodium-free’.

1 - Urinary retention - Uncontrolled narrow angle glaucoma - Myasthenia gravis - Severe ulcerative colitis - Toxic megacolon